Adam M. Koppel is a Partner at Bain Capital Life Sciences. He initially joined Bain Capital Public Equity in 2003, where he was a leader within the healthcare sector until 2014. From 2014 to 2016, Dr. Koppel was EVP of Corporate Development and Chief Strategy Officer at Biogen. Prior to joining Bain Capital Public Equity in 2003, Dr. Koppel was an associate principal at McKinsey & Co in New Jersey where he served a variety of healthcare
companies.

Dr. Koppel sits on the Board of Directors of Areteia Therapeutics, Cardurion Pharmaceuticals and Kailera Therapeutics and previously served on the Board of Directors of Aptinyx (NASD: APTX), Cerevel Therapeutics (NASD: CERE), Dicerna Pharmaceuticals (NASD: DRNA), Foghorn Therapeutics (NASD: FHTX), PTC Therapeutics (NASD: PTCT), Solid Biosciences (NASD: SLDB), Trevena, Inc (NASD: TRVN) and ViaCyte Inc.

Dr. Koppel is currently chairman of the Board of Trustees of the Boston Museum of Science, and also serves on the boards of the Newton-Wellesley Hospital, CJP Boston and The William Penn Charter School in Philadelphia. He sits on the Investment Committee of the Society for Neuroscience, co-chairs the Harvard Medical School Discovery Council, and serves on the Mass General Brigham Innovation Growth Board.

Dr. Koppel received an MD and PhD in Neuroscience from the University of Pennsylvania School of Medicine. He also received an MBA from The Wharton School at the University of Pennsylvania, where he was a Palmer Scholar. He graduated magna cum laude from Harvard University with an AB and AM in History and Science.